Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Current treatment practices in metastatic castration resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.05.12
Views: 3424

Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo Berruti

This roundtable discussion held in Vienna, Austria, on 16 May 2012, focuses on recent advances in treatment options in metastatic castration resistant prostate cancer post-docetaxel. Chaired by Professor Joachim Bellmunt from Spain, the discussion includes Professor Nicolas Mottet from France, Professor Alfredo Berruti from Italy and Professor Noel Clarke from the UK. 


New treatment possibilities available in metastatic castration resistant prostate cancer post-docetaxel have resulted in improvements in overall survival. The experts briefly review the research landscape and study data.


Defining individual management strategies for high-risk disease in the era of these novel treatment options is a challenge faced by many clinicians in daily clinical practice. The experts discuss how to best manage and implement the new treatment options, including issues such as how these agents might be used sequentially or in combination, and how patients should be selected.


Currently, parameters for assessing disease progression are an important tool for making treatment decisions in metastatic castration resistant prostate cancer post-docetaxel. But is PSA the main progression parameter clinicians need to review when making treatment decisions? The experts consider progression parameters including the role of PSA, patient risk profiles and pace of disease.


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation